| Item Type | Name |
|
Concept
|
Hepatitis B, Chronic
|
|
Concept
|
Hepatitis C, Chronic
|
|
Academic Article
|
High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.
|
|
Academic Article
|
Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.
|
|
Academic Article
|
A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C.
|
|
Academic Article
|
Mixed cryoglobulinemia in chronic hepatitis C infection. A clinicopathologic analysis of 10 cases and review of recent literature.
|
|
Academic Article
|
High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial.
|
|
Academic Article
|
Inflammatory markers in chronic hepatitis C.
|
|
Academic Article
|
Frequency and distribution of DNA fragmentation as a marker of cell death in chronic liver diseases.
|
|
Academic Article
|
Interleukin-8 and hIRH (SDF1-alpha/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C.
|
|
Academic Article
|
Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C.
|
|
Academic Article
|
Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects.
|
|
Academic Article
|
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.
|
|
Academic Article
|
IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy.
|
|
Academic Article
|
Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.
|
|
Academic Article
|
Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.
|
|
Academic Article
|
Outcomes research in chronic viral hepatitis C: effects of interferon therapy.
|
|
Academic Article
|
Management of recurrent hepatitis C after liver transplantation: a concise review.
|
|
Academic Article
|
Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial.
|
|
Academic Article
|
Iron as a comorbid factor in chronic viral hepatitis.
|
|
Academic Article
|
Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.
|
|
Academic Article
|
Iron as a co-morbid factor in nonhemochromatotic liver disease.
|
|
Academic Article
|
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
|
|
Academic Article
|
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
|
|
Academic Article
|
Hemochromatosis mutations in Iranians with hepatitis B virus infection.
|
|
Academic Article
|
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C.
|
|
Academic Article
|
Evolution of the intrahepatic T cell repertoire during chronic hepatitis C virus infection.
|
|
Academic Article
|
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
|
|
Academic Article
|
No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C.
|
|
Academic Article
|
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
|
|
Academic Article
|
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
|
|
Academic Article
|
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
|
|
Academic Article
|
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
|
|
Academic Article
|
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
|
|
Academic Article
|
Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.
|
|
Academic Article
|
Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials.
|
|
Academic Article
|
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
|
|
Academic Article
|
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
|
|
Academic Article
|
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
|
|
Academic Article
|
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.
|
|
Academic Article
|
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.
|
|
Academic Article
|
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
|
|
Academic Article
|
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
|
|
Academic Article
|
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
|
|
Academic Article
|
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
|
Academic Article
|
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
|
Academic Article
|
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
|
|
Academic Article
|
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
|
|
Academic Article
|
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.
|
|
Academic Article
|
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
|
|
Academic Article
|
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
|
|
Academic Article
|
Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.
|
|
Academic Article
|
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review.
|
|
Academic Article
|
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
|
Academic Article
|
Genetic variations in heme oxygenase-1 and chronic hepatitis.
|
|
Academic Article
|
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
|
|
Academic Article
|
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
|
|
Academic Article
|
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
|
|
Academic Article
|
Parallel microRNA and mRNA expression profiling of (genotype 1b) human hepatoma cells expressing hepatitis C virus.
|
|
Academic Article
|
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
|
|
Academic Article
|
Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.
|
|
Academic Article
|
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.
|
|
Academic Article
|
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
|
|
Academic Article
|
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
|
|
Academic Article
|
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
|
|
Academic Article
|
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C.
|
|
Academic Article
|
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
|
|
Academic Article
|
A naturally occurring human/hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture.
|
|
Academic Article
|
Chinese medicine for treatment of chronic hepatitis B.
|
|
Academic Article
|
Hepatitis C, porphyria cutanea tarda and liver iron: an update.
|
|
Academic Article
|
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.
|
|
Academic Article
|
Risk factors for porphyria cutanea tarda -the iron/HFE connection.
|
|
Academic Article
|
Cytoskeletal proteins: shaping progression of hepatitis C virus-induced liver disease.
|
|
Academic Article
|
Chronic hepatitis E with neurologic manifestations and rapid progression of liver fibrosis in a liver transplant recipient.
|
|
Academic Article
|
MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA.
|
|
Academic Article
|
Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
|
|
Grant
|
HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS
|